Morphine Exposure Reduced Later Cannabinoid Antinociceptive Potency in Monkeys
Previous opioid treatment can change later cannabinoid responses even without prior cannabinoid dosing. In a rhesus-monkey experiment, repeated morphine reduced the antinociceptive potency of several cannabinoid agonists.
The exposure history was the intervention
Four monkeys received repeated morphine. Researchers compared dose-response relationships for morphine, a kappa-opioid agonist and cannabinoid agonists using warm-water tail withdrawal. The cannabinoids included THC, WIN55,212 and CP55,940.
The magnitude was drug-dependent
The abstract reports reduced potency across the tested drugs, with the largest shifts for morphine and two synthetic cannabinoid agonists. Signs associated with withdrawal appeared after morphine discontinuation. The findings describe cross-tolerance under conditions also producing physical dependence.
A potency shift does not answer every safety question
A greater dose needed to change a tail-withdrawal response does not establish reduced sensitivity to respiratory depression, intoxication or impaired judgment. Nor does an animal's response establish how a patient will experience an ordinary cannabis product.
The study's final suggestion about lower-dose opioid–cannabinoid mixtures was a possibility for future investigation, not a tested outcome of this regimen. It should not be presented as proof that combinations avoid tolerance. The distinction between prior exposure and simultaneous treatment is particularly important when comparing this work with combination studies. Both can be informative while measuring different causal questions.
Related: interpreting cannabis tolerance claims.
Research cited
Gerak LR; Zanettini C; Koek W; France CP. Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys. Psychopharmacology (2015). doi:10.1007/s00213-015-4023-x. Findings discussed from the study abstract.
